Evidence map›Paper›PMID 41043854›Full record

ArticleJournal for immunotherapy of cancer2025

T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer.

Johanna M Schafer, No-Joon Song, Tong Xiao, Timothy D Gauntner, Kyeong Joo Jung, Emily G Fitts, Krishan Kumar, Hyeong Seon Jeon, Ryan A Elaoud, Kelsi Reynolds and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Johanna M Schafer *Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.ORCID http://orcid.org/0000-0001-7834-5621
No-Joon Song *Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.ORCID http://orcid.org/0009-0002-0947-0597
Tong XiaoComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Timothy D GauntnerComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Kyeong Joo JungComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Emily G FittsComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.ORCID http://orcid.org/0009-0004-9211-4300
Krishan KumarComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Hyeong Seon JeonDepartment of Computer Science, The Ohio State University, Columbus, Ohio, USA.
Ryan A ElaoudThe Ohio State University, Columbus, Ohio, USA.
Kelsi ReynoldsComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Vincent M CarusoConvergent Genomics Inc, South San Francisco, California, USA.
Trevor G LevinConvergent Genomics Inc, South San Francisco, California, USA.
David McConkeyJohns Hopkins Medicine, Baltimore, Maryland, USA.
Cheryl T LeeComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Kamal S PoharComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Steven K ClintonComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
William CarsonComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Dongjun ChungComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.ORCID http://orcid.org/0000-0002-8072-5671
Zihai LiComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA D.Sundi@osumc.edu Zihai.Li@osumc.edu.ORCID http://orcid.org/0000-0003-4603-927X
Debasish SundiComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA D.Sundi@osumc.edu Zihai.Li@osumc.edu.ORCID http://orcid.org/0000-0001-6980-4777

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
The Role of the Y Chromosome in Bladder Tumor Development, Growth And ProgressionP01CA278732 · NCI · CEDARS-SINAI MEDICAL CENTER · PI Xue Sean Li · 2023 to 2026
$10.7M
Defining epigenetic vulnerabilities of subtype-specific lung cancersK22CA201036 · NCI · UNIVERSITY OF KENTUCKY · PI BRAINSON, CHRISTINE FILLMORE · 2016 to 2018
$482k
NCI NIH HHS K22 CA201036NCI NIH HHS P01 CA278732NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

backgroundBladder cancer is unique among visceral malignancies in that urine, which can be easily obtained, has prolonged contact with bladder tumors. Urinary biomarkers offer the potential to provide insight into the host and tumor immune microenvironment to guide therapeutic strategies. We evaluated the immune cellular composition of urine (urine-derived lymphocytes (UDLs)) versus tumor (tumor-infiltrating lymphocytes (TILs)).

methodsWe employed high-dimensional flow cytometry analyses on immune cells from tumors (TILs), urine (UDLs), and peripheral blood (peripheral blood mononuclear cells) among patients with bladder cancer. We performed multiplexed immunofluorescence (mIF) of matched tumors to provide spatial context to our findings, comparing deep/invasive and superficial/urine-facing regions of matched tumors.

resultsOur findings suggest that the CD4

conclusionsAssessment of UDLs opens avenues of non-invasive biomarker development in clinical settings where bladder cancer TILs are hypothesized to predict clinical response. UDLs may also reflect sex-based differences in antitumor immunity.

Indexed as

Lymphocytes, Tumor-InfiltratingT-Lymphocyte SubsetsUrinary Bladder NeoplasmsAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedSex FactorsTumor MicroenvironmentBiomarkers, Tumorbiomarkerbladder cancergenitourinary cancerT celltumor infiltrating lymphocyte - TIL

Identifiers

PMID41043854
PMCPMC12496083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.